Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2020;31(3):362-5
Article Links
Acute Coronary Syndrome in a Male with Elevated Anti-Cyclic Citrullinated Peptide and no Evidence of Longstanding Rheumatoid Arthritis
Georges El Hasbani, Ziyad Ghazzal, Habib Dakik, Lamiaa Hamie, Imad Uthman
Authors Information

Department of Internal Medicine, American University of Beirut, Lebanon

Georges El Hasbani, Lamiaa Hamie, Imad Uthman

Keywords: Acute coronary syndrome, rheumatoid arthritis, biomarkers, risk factors
References
  1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012 Sep;71(9):1524-9.
  2. del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 2006 Jun;24(3):281-6.
  3. Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, Krishnan E, et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013 Jul;65(7):1719-24.
  4. Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004 Sep;63(9):1090-5.
  5. Arnab B, Biswadip G, Arindam P, Shyamash M, Anirban G, Rajan P. Anti-CCP antibody in patients with established rheumatoid arthritis: Does it predict adverse cardiovascular profile? J Cardiovasc Dis Res 2013 Jun;4(2):102-6.
  6. Cambridge G, Acharya J, Cooper JA, Edwards JC, Humphries SE. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013 May 1;228(1):243-6.
  7. Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer Is Associated with Increased Cardiovascular Risk [Internet]. ACR Meeting Abstracts. [cited 2020 Feb 15]. Available from: https://acrabstracts.org/abstract/elevated-anti-cyclic-citrullinated-peptide-antibody-titer-is-associated-with-increased-cardiovascular-risk/
  8. Fantus SA, Heisler A, Briones MR, Martin B, Correia C, Ostrowski RA. Association of Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer with Increased Cardiovascular Risk. J Rheumatol Arthritis Res (1):6.
  9. Hermans MPJ, van der Velden D, Montero Cabezas JM, Putter H, Huizinga TWJ, Kuiper J, et al. Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. Int J Cardiol 2017 Aug 1;240:20-4.
  10. Innala L, Möller B, Ljung L, Magnusson S, Smedby T, Södergren A, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011;13(4):R131.